The phrase growth hormone secretagogue covers two families of peptides that act at two different receptors on the same cell. Treating them as one category is the most common mistake in this corner of the literature. This article separates the families, explains what the DAC modification changes, and describes the preclinical models the compounds appear in.
One pituitary, two receptors
Somatotroph cells in the anterior pituitary store growth hormone and release it in pulses. Two receptors on those cells drive release through distinct signaling routes.
- The GHRH receptor responds to growth hormone releasing hormone from the hypothalamus. It is a class B G protein-coupled receptor signaling mainly through Gs, cyclic AMP and protein kinase A. Its output is modulated by somatostatin, the inhibitory arm of the axis.
- The growth hormone secretagogue receptor, GHSR-1a, is the receptor for ghrelin, identified in 1999 as an acylated peptide from the stomach. It signals mainly through Gq and the phospholipase C and calcium route, and it also acts at the hypothalamus to reduce somatostatin tone.
Two receptors, two second-messenger systems, one secretory output. That structure is the whole reason the compounds below fall into two groups.
Family one: GHRH analogs
Native GHRH is 44 residues, and the first 29 contain essentially all the receptor activity. The practical problem is dipeptidyl peptidase-4, which clips the peptide at the N-terminus within minutes. Every member of this family is a variation on protecting that bond.
Sermorelin is GRF(1-29) amide, the truncated fragment with no further protection, and it is correspondingly short-lived in circulation. Tesamorelin is a GRF(1-44) analog carrying a trans-3-hexenoyl group on the N-terminus, which blocks the cleavage site and extends measurable half-life. Modified GRF(1-29), commonly sold as CJC-1295 without DAC, carries four amino acid substitutions that resist DPP-4 and reduce degradation while keeping the sequence otherwise close to the native fragment.
Family two: ghrelin receptor agonists
These do not resemble GHRH. They are short synthetic peptides that act at GHSR-1a, the family that began with the growth hormone releasing peptides described by Bowers and colleagues before the endogenous ligand was known. GHRP-6 is the classic example and is notable for also stimulating appetite-related signaling in animal models. Ipamorelin is a pentapeptide from the same program, characterized as the first selective member of the class because in the original rodent and pituitary-cell work it released growth hormone with minimal effect on adrenocorticotropic hormone, cortisol or prolactin. That selectivity is why it is the one most often chosen when a study wants a clean secretagogue signal without confounding endocrine variables.
Why labs pair one from each family
Because the two receptors are not redundant. In pituitary cell preparations, combining a GHRH-receptor agonist with a ghrelin-receptor agonist produces a larger release than either alone, and the effect has been described as more than additive. The mechanistic account is straightforward: the cyclic AMP arm and the calcium arm converge on the same secretory machinery, and the ghrelin-receptor side additionally reduces somatostatin restraint. Pairing also preserves pulsatility, since the release still depends on the cell's own stores and feedback rather than bypassing them.
That is the logic behind supplying the two in one vial, as in the CJC-1295 no-DAC and ipamorelin preparation and the other combinations in our blend catalog. A blend vial lists both masses, and each component gets its own concentration in your notes. Our reconstitution guide works through that arithmetic, and the same pairing logic in a different context is covered in why labs run BPC-157 and TB-500 together.
DAC and no-DAC are two different compounds
The name CJC-1295 is used for both, which causes constant confusion. DAC stands for drug affinity complex, a maleimidoproprionic acid linker that forms a covalent bond with a cysteine residue on circulating albumin. With that linker attached, the peptide is carried by albumin and its half-life extends from minutes to days. Without it, modified GRF(1-29) is a short-acting peptide.
| Attribute | Modified GRF(1-29), no DAC | CJC-1295 with DAC |
|---|---|---|
| Albumin linker | None | Maleimidoproprionic acid, binds albumin covalently |
| Measured half-life | Minutes | Days |
| Resulting exposure profile | Short pulse, returns to baseline quickly | Sustained elevation, pulse structure blunted |
| Usual research rationale | Studying pulsatile release and pairing effects | Studying sustained receptor occupancy |
A protocol written for one is not a protocol for the other. If a certificate or a vendor page does not state DAC status explicitly, that is a question to ask before the vial goes in the freezer.
The models these compounds appear in
The foundational work is in isolated rat pituitary cell cultures, where growth hormone release into the medium is measured directly against receptor agonism. Beyond that, the literature runs through rodent studies measuring circulating growth hormone and insulin-like growth factor 1, hypothalamic and pituitary gene expression, and body-composition endpoints in animals. Receptor-binding and signaling assays in transfected cell lines fill in selectivity questions, which is how the ACTH and prolactin selectivity of ipamorelin was established. All of it is preclinical. Nothing in this article describes use in people.
The most selective member of the ghrelin-receptor group gets its own article in what is ipamorelin.
Frequently asked questions
Why not use growth hormone itself in a model?
Because secretagogues answer a different question. Direct administration bypasses the pituitary and abolishes pulsatility, while a secretagogue depends on the cell's own stores and the feedback loop around it. If the axis is the subject of the study, replacing it defeats the experiment.
Is ipamorelin simply a better GHRP-6?
Not better, more selective. In the original characterization ipamorelin released growth hormone with little effect on ACTH, cortisol and prolactin, while GHRP-6 has broader endocrine and appetite-related activity. Which is preferable depends on whether those additional effects are a confounder or the subject.
What does the certificate need to show for a blend vial?
Identity and purity for each component, not a single combined figure, plus the mass of each. Our guide to reading a COA covers what a two-component certificate should contain.
References
- Guillemin and colleagues, 1982, Science, Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.
- Bowers and colleagues, 1984, Endocrinology, On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.
- Raun and colleagues, 1998, European Journal of Endocrinology, Ipamorelin, the first selective growth hormone secretagogue.
- Kojima and colleagues, 1999, Nature, Ghrelin is a growth-hormone-releasing acylated peptide from stomach.
Research use only. This article describes laboratory and preclinical research. Homegrown Peptides products are not for human or animal use, are not drugs, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice or a protocol.
